Telix Pharmaceuticals Limited (TLX,TLX.AX) reported that its operating profit for the first-half of 2025 dropped to US$10.4 million from US$27.7 million in the prior year. Loss before tax was US$4.8 million compared to profit of US$22.9 million in the prior year. The latest period results included US$12.4 million in non-cash finance costs associated with convertible bonds issued in July 2024 and increased amortization cot of US$9.5 million following RLS acquisition.
Revenue for the period was US$390.4 million, up 63% from last year.
Telix confirmed fiscal year 2025 revenue guidance of US$770 million to US$800 million.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.